A Phase 1, Open-label, Parallel-group, Multiple-dose Study to Evaluate the Pharmacokinetics of Bulevirtide in Participants With Normal and Impaired Hepatic Function
Latest Information Update: 03 Feb 2025
At a glance
- Drugs Bulevirtide (Primary)
- Indications Hepatitis D
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
Most Recent Events
- 29 Jan 2025 Status changed from recruiting to completed.
- 05 Apr 2023 New trial record
- 30 Mar 2023 Status changed from not yet recruiting to recruiting.